澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ISLAND PHARMACEUTICALS LTD

0.355

-0.005-1.39%

成交量：31.62萬

成交額：11.38萬

市值：1.05億

市盈率：-15.70

高：0.365

開：0.365

低：0.355

收：0.360

52周最高：0.630

52周最低：0.120

股本：2.95億

流通股本：1.11億

量比：1.00

換手率：0.29%

股息：- -

股息率：- -

每股收益(TTM):-0.023

每股收益(LYR):-0.023

淨資產收益率：-90.37%

總資產收益率：-49.16%

市淨率：14.62

市盈率(LYR):-15.70

資料載入中...

總覽公司新聞資訊公告

Island Pharmaceuticals：美國FDA通知需額外時間完成對公司近期提交材料的回覆

ISLAND PHARMACEUTICALS LTD 就Galidesivir依據FDA動物規則開發路徑尋求進一步澄清

Island Pharmaceuticals Ltd將就擬議臨床研究設計尋求指導，Galidesivir有望獲得優先審評券資格

ISLAND PHARMACEUTICALS LTD：FDA批准在加利昔韋開放性試驗性新藥申請下召開C類會議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ILA.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ILA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","market":"AU","secType":"STK","nameCN":"ISLAND PHARMACEUTICALS LTD","latestPrice":0.355,"timestamp":1771909920000,"preClose":0.36,"halted":0,"volume":316164,"delay":0,"changeRate":-0.013888888888888902,"nameEN":"ISLAND PHARMACEUTICALS LTD","floatShares":110756995,"shares":294766682,"eps":-0.022614,"marketStatus":"未開盤","change":-0.005,"latestTime":"02-24 16:12:00 AEDT","open":0.365,"high":0.365,"low":0.355,"amount":113798,"amplitude":0.027778,"askPrice":0.355,"askSize":23100,"bidPrice":0.35,"bidSize":60700,"shortable":3,"etf":0,"ttmEps":-0.022614,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1771974000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.36,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":0.9959251247426081,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","floatShares":110756995,"roa":"-49.16%","roe":"-90.37%","lyrEps":-0.022614,"volumeRatio":0.9959251247426081,"shares":294766682,"dividePrice":0,"high":0.365,"amplitude":0.027778,"preClose":0.36,"low":0.355,"week52Low":0.12,"pbRate":"14.62","psRate":"880.01","week52High":0.63,"institutionHeld":0,"latestPrice":0.355,"committee":0.448687,"eps":-0.022614,"divideRate":0,"volume":316164,"delay":0,"ttmEps":-0.022614,"open":0.365,"prevYearClose":0.43,"prevWeekClose":0.37,"prevMonthClose":0.39,"prevQuarterClose":0.43,"fiveDayClose":0.365,"twentyDayClose":0.42,"sixtyDayClose":0.55,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ILA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ILA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ILA.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151552066","title":"Island Pharmaceuticals：美國FDA通知需額外時間完成對公司近期提交材料的回覆","url":"https://stock-news.laohu8.com/highlight/detail?id=1151552066","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151552066?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 05:43","pubTimestamp":1767562991,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd（ASX: ILA）近日披露，美国食品药品监督管理局（FDA）已向公司发出通知，表示需要更多时间来最终确定对其近期提交材料的正式回复。这一进展意味着FDA对该公司提交内容的审核流程仍在进行中，但完成评估所需时间较原预期有所延长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"1149987014","title":"ISLAND PHARMACEUTICALS LTD 就Galidesivir依據FDA動物規則開發路徑尋求進一步澄清","url":"https://stock-news.laohu8.com/highlight/detail?id=1149987014","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149987014?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 05:43","pubTimestamp":1767562991,"startTime":"0","endTime":"0","summary":"ISLAND PHARMACEUTICALS LTD 已就抗病毒药物Galidesivir依据美国食品药品监督管理局（FDA）的“动物规则”进行开发的路径，向监管机构寻求进一步的说明和澄清。此举旨在更清晰地理解在该法规框架下推进药物研发的具体要求和流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"1170573251","title":"Island Pharmaceuticals Ltd將就擬議臨床研究設計尋求指導，Galidesivir有望獲得優先審評券資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1170573251","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170573251?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 07:32","pubTimestamp":1758238336,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd宣布，公司将就拟议的临床研究设计方案寻求监管机构指导，同时评估其抗病毒药物Galidesivir获得优先审评券的资格。\n该公司此举旨在推进Galidesivir的临床开发进程，通过与监管部门的沟通确保研究设计符合要求。优先审评券机制可为符合条件的药物提供加速审批通道，有助于缩短上市时间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"1181195802","title":"ISLAND PHARMACEUTICALS LTD：FDA批准在加利昔韋開放性試驗性新藥申請下召開C類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1181195802","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181195802?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 07:31","pubTimestamp":1758238272,"startTime":"0","endTime":"0","summary":"ISLAND PHARMACEUTICALS LTD宣布，美国食品药品监督管理局（FDA）已批准在其药物加利昔韦的开放性试验性新药申请框架下召开C类会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}